The global hepatocellular carcinoma market size was valued at around USD 1658.58 Million in 2022 , is projected to reach around USD 4410.72 Million by 2031 and expanding at a CAGR of 11.48% during the forecast period, 2023–2031. The growth of the market is attributed to increasing incidence of hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) is a kind of primary liver cancer stage that begins in the cells of the liver, or hepatocytes. Patients with hepatitis C, B, cirrhosis, diabetes, and obesity are likely to develop the cancer condition. Imaging techniques such as ultrasound, MRI, CT scan, and liver biopsy are used to diagnose hepatocellular cancer. Hepatocellular carcinoma is treated with a combination of chemotherapy, radiation treatment, ablation therapy, and targeted medication therapy. Majority of HCC patients are diagnosed at the end-stage of liver dysfunction. The death rate is nearly equal to the incidence rate, due to the poor prognosis of the illness. Therefore, early identification of the cancer is a critical metric for improving the survival of patients with hepatocellular carcinoma.
The COVID-19 pandemic affected the hepatocellular cancer market. In May 2020, according to a study published in the National Library of Medicine titled "Impacts of COVID-19 on Liver Cancers: During and After the Pandemic," hepatocellular carcinoma (HCC) patients are more vulnerable to the effects of coronavirus than other cancer patients, as the hepatic injury caused by SARS-CoV-2 complicates the existing hepatitis virus infection and cirrhosis. As a result of the COVID-19 pandemic, healthcare priorities shifted, potentially affecting HCC management.
Market Trends, Drivers, Restraints, and Opportunities
-
Rising mortality associated with liver cancer across the globe is expected to drive the market.
-
Increasing geriatric population and changing lifestyle is projected to propel the market during the forecast period.
-
Few diagnoses and poor efficacy of current therapeutics is anticipated to hinder the market.
-
Lack of awareness regarding the disease is expected to hamper the market in the coming years.
-
Advancements in treatment options for hepatocellular carcinoma is projected to create lucrative opportunities for market players.
Scope of the Report
The report on the global hepatocellular carcinoma market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Hepatocellular Carcinoma Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Diagnosis (Imaging Tests [MRI and CT], Blood Tests, and Liver Biopsy), Drug Class (PD-1/PD-L1 Inhibitors and Tyrosine Kinase Inhibitors), Treatments (Immunotherapy, Molecularly Targeted Therapy, Chemotherapy, and Others), and End-users (Cancer Centers, Hospitals, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Bristol-Myers Squibb Company; AstraZeneca PLC; Bayer AG; Celgene Corporation; Eisai Co. Ltd; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; and Pfizer Inc.
|
Market Segment Insights
Imaging test segment to expand at a considerable CAGR
On the basis of diagnosis, the hepatocellular carcinoma market is segregated into imaging tests, blood tests, and liver biopsy. The imaging test segment is further classified as MRI and CT. The imaging tests segment is projected to expand at a considerable CAGR during the forecast period. Cross-sectional imaging with Computed Tomography scanning (CT) is commonly used to detect hepatocellular carcinoma. Magnetic Resonance Imaging (MRI) detects lesions less than 1cm in diameter. The blood test segment is anticipated to account for a major market share during the forecast period. There is a specific test that is used for the diagnosis of hepatocellular carcinoma. This test measures the level of the protein (alfa-fetoprotein) in serum.
PD-1/PD-L1 inhibitors segment to hold a significant share of the market
Based on drug class, the market is divided into PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors. The PD-1/PD-L1 inhibitors segment is expected to hold a significant share of the market in the coming years, as it is a drug treatment which helps the body recognize and attack cancerous cells. The tyrosine kinase inhibitors segment accounts for a significant market share, as it is able to control the disease effectively.
Chemotherapy segment to expand at a substantial CAGR
On the basis of treatments, the hepatocellular carcinoma market is segmented into immunotherapy, molecularly targeted therapy, chemotherapy, and others. The chemotherapy segment is anticipated to expand at a substantial CAGR during the forecast period, as chemotherapy is widely used in the treatment of hepatocellular carcinoma, as it is resectable cancer. The immunotherapy segment is expected to hold a significant share of the market. Immunotherapy provides the body additional components to enhance the immune response and boost immune cells to help them eliminate cancer.
Cancer centers segment to register considerable market share
Based on end-users, the market is segmented into cancer centers, hospitals, and others. The cancer centers segment is projected to register considerable market share in the coming years, due to increased patient visits for treatments against liver cancer disorders. The hospitals segment is expected to register substantial CAGR, due to increasing geriatric population and rising cases of diabetes and high blood pressure.
North America is anticipated to constitute a key market share
In terms of regions, the hepatocellular carcinoma market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a key share of the market during the forecast period, owing to increasing prevalence of liver cancer among people in the region. The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to technological advancements in drug development and increasing R&D activities.
Segments
The global hepatocellular carcinoma market has been segmented on the basis of
Diagnosis
- Imaging Tests
- Blood Tests
- Liver Biopsy
Drug Class
- PD-1/PD-L1 Inhibitors
- Tyrosine Kinase Inhibitors
Treatments
- Immunotherapy
- Molecularly Targeted Therapy
- Chemotherapy
- Others
End-users
- Cancer Centers
- Hospitals
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Bayer AG
- Celgene Corporation
- Eisai Co. Ltd
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- Pfizer Inc.
Competitive Landscape
Key players competing in the global hepatocellular carcinoma market are Bristol-Myers Squibb Company; AstraZeneca PLC; Bayer AG; Celgene Corporation; Eisai Co. Ltd; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; and Pfizer Inc.
Key market players are increasing their investments in drug research and development to develop effective treatments for hepatocellular carcinoma. Manufacturers are concentrating on strategic partnerships to jointly develop and market immunotherapies for a wide spectrum of malignancies. These companies adopt acquisitions and collaborations to boost their market share.
Request For Customization
Enquiry Before Buying
Speak With Analyst
